![Amer Zeidan: Just an unbelievable cascade of news for magrolimab](https://oncodaily.com/pub/uploads/2023/09/BA150FFD-7397-4369-97CB-A64E29A5CDFC-e1699989222883.jpeg)
Amer Zeidan: Just an unbelievable cascade of news for magrolimab
Amer Zeidan shared on X:
“Just an unbelievable cascade of news for magrolimab … Gilead Sciences Passes Enrollment for Cancer Treatment in Solid Tumor Trials.”
View additional information.
Source: Amer Zeidan/X
Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center. Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023